Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.47 |
| ▸ | SCN1A | P35498 | 3/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441963 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL1293117 | 0.79 | LMNA (0.50) | CHRM2LMNACHRM1HRH1HTR2A | |
| SCHEMBL24802072 | 0.78 | KCNA5 (0.49) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL18966264 | 0.78 | KCNA5 (0.49) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL290075 | 0.78 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL17071880 | 0.78 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL23518093 | 0.77 | KCNA5 (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL13273737 | 0.76 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL3910230 | 0.75 | TSHR (0.62) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL19267203 | 0.75 | KCNA5 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | SLC6A2 4742/4885SLC6A4 4710/4885SLC6A3 4709/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SLC6A2 4853/4885SLC6A4 4876/4885SLC6A3 4779/4885 |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | SLC6A2 4853/4885SLC6A4 4876/4885SLC6A3 4779/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SLC6A2 4853/4885SLC6A4 4876/4885SLC6A3 4779/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | SLC6A2 4742/4885SLC6A4 4710/4885SLC6A3 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.